Back to Search Start Over

Surgical Resection of Pulmonary Metastases from Melanoma in Oligometastatic Patients: Results from a Multicentric Study in the Era of Immunoncology and Targeted Therapy

Authors :
Meacci, Elisa
Nachira, Dania
Congedo, Maria Teresa
Ibrahim, M.
Pariscenti, G.
Petrella, F.
Casiraghi, M.
De Stefani, A.
del Regno, L.
Peris, Ketty
Triumbari, E. K. A.
Schinzari, Giovanni
Rossi, E.
Petracca-Ciavarella, L.
Vita, Maria Letizia
Chiappetta, M.
Siciliani, A.
Peritore, V.
Manitto, M.
Morelli, L.
Zanfrini, E.
Tabacco, Diomira
Calabrese, Giuseppe
Bardoni, C.
Evangelista, Jessica
Spaggiari, L.
Margaritora, Stefano
Meacci E. (ORCID:0000-0001-8424-3816)
Nachira D. (ORCID:0000-0003-2937-9678)
Congedo M. T.
Peris K. (ORCID:0000-0002-5237-0463)
Schinzari G. (ORCID:0000-0001-6105-7252)
Vita M. L.
Tabacco D.
Calabrese G.
Evangelista J.
Margaritora S. (ORCID:0000-0002-9796-760X)
Meacci, Elisa
Nachira, Dania
Congedo, Maria Teresa
Ibrahim, M.
Pariscenti, G.
Petrella, F.
Casiraghi, M.
De Stefani, A.
del Regno, L.
Peris, Ketty
Triumbari, E. K. A.
Schinzari, Giovanni
Rossi, E.
Petracca-Ciavarella, L.
Vita, Maria Letizia
Chiappetta, M.
Siciliani, A.
Peritore, V.
Manitto, M.
Morelli, L.
Zanfrini, E.
Tabacco, Diomira
Calabrese, Giuseppe
Bardoni, C.
Evangelista, Jessica
Spaggiari, L.
Margaritora, Stefano
Meacci E. (ORCID:0000-0001-8424-3816)
Nachira D. (ORCID:0000-0003-2937-9678)
Congedo M. T.
Peris K. (ORCID:0000-0002-5237-0463)
Schinzari G. (ORCID:0000-0001-6105-7252)
Vita M. L.
Tabacco D.
Calabrese G.
Evangelista J.
Margaritora S. (ORCID:0000-0002-9796-760X)
Publication Year :
2023

Abstract

In the last decade, the emergence of effective systemic therapies (ESTs) in the form of both targeted and immuno-based therapies has revolutionized the treatment of patients with advanced stage III and stage IV melanoma. Even though lungs represent the most frequent site of melanoma metastases, only limited data are available on the role of surgery in isolated pulmonary metastases from malignant melanoma (PmMM) in the era of ESTs. The aim of this study is to describe the outcomes of patients who underwent metastasectomy of PmMM in the era of ESTs, in order to identify prognostic factors affecting survival and to provide a framework for more informed patient selection of treatmeant with lung surgery in the future. Clinical data of 183 patients who underwent metastasectomy of PmMM between June 2008 and June 2021 were collected among four Italian Thoracic Centers. The main clinical, surgical and oncological variables reviewed were: sex, comorbidities, previous oncological history, melanoma histotypes and primary site, date of primary cancer surgical treatment, melanoma growth phase, Breslow thickness, mutation pattern disease, stage at diagnosis, metastatic sites, DFI (Disease Free Interval), characteristics of lung metastases (number, side, dimension, type of resection), adjuvant therapy after lung metastasectomy, site of recurrence, disease-free survival (DFS) and cancer-specific survival (CSS; defined as the time interval between the first melanoma resection or lung metastasectomy and death from cancer). All patients underwent surgical resection of the primary melanoma before lung metastasectomy. Twenty-six (14.2%) patients already had a synchronous lung metastasis at the time of primary melanoma diagnosis. A wedge resection was performed in 95.6% of cases to radically remove the pulmonary localizations, while an anatomical resection was necessary in the remaining cases. The incidence of major post-operative complications was null, while only 21 patients (11.5%) dev

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1397546076
Document Type :
Electronic Resource